• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

眼表疾病:春季角结膜炎病例。

Ocular surface disease: a case of vernal keratoconjunctivitis.

机构信息

Pennsylvania College of Optometry at Salus University, 8360 Old York Road, Elkins Park, PA 19027, USA.

出版信息

Cont Lens Anterior Eye. 2011 Feb;34(1):39-44. doi: 10.1016/j.clae.2010.09.002. Epub 2010 Oct 25.

DOI:10.1016/j.clae.2010.09.002
PMID:20971677
Abstract

Vernal keratoconjunctivitis (VKC) is a recurrent, chronic allergic inflammation of the ocular surface associated with remodeling of the cornea and conjunctiva, with a potential to adversely affect the patient's vision and quality of life. It affects mainly children and young adults. The purpose of this interventional case report is to present a typical case of limbal VKC, which was unresponsive to antiallergic treatment alone. A 5-year-old boy, who was previously unsuccessful with conventional anti-allergic therapy alone, presented with clinicopathological features pathognomonic of limbal VKC. The patient was successfully managed with a combination of palliative, anti-allergic and anti-inflammatory therapy. Prophylaxis with an anti-allergic pharmaceutical agent was initiated for long term use to prevent the release of allergic mediators. This case highlights the importance of prescribing the most appropriate pharmaceutical medication for VKC since conjunctival fibroproliferative lesions are often resistant to anti-allergy therapy. Allergic inflammatory mediators are responsible for the fibroproliferative changes of the conjunctiva and corneal lesions in VKC. Thus, it is crucial to prescribe the most appropriate pharmaceutical medication that will prevent the release of allergic inflammatory mediators, control the allergic inflammatory cascade and prevent ocular surface damage. The fine points of this case are presented with a review of applicable literature.

摘要

春季角结膜炎(VKC)是一种反复发作的、慢性的眼表过敏炎症,与角膜和结膜的重塑有关,有可能对患者的视力和生活质量产生不利影响。它主要影响儿童和年轻人。本介入性病例报告的目的是介绍一个典型的角膜缘型 VKC 病例,该病例对单独的抗过敏治疗反应不佳。一名 5 岁男孩,曾单独接受常规抗过敏治疗失败,表现出角膜缘型 VKC 的特征性临床病理特征。该患者通过姑息治疗、抗过敏和抗炎治疗联合成功治疗。为了预防过敏介质的释放,开始使用预防性抗过敏药物进行长期治疗。该病例强调了为 VKC 开处方最合适的药物的重要性,因为结膜纤维增生性病变通常对抗过敏治疗有抗性。过敏炎症介质是 VKC 中结膜和角膜病变的纤维增生性改变的原因。因此,至关重要的是开处方最合适的药物,以防止过敏炎症介质的释放,控制过敏炎症级联反应,并预防眼表损伤。本文通过回顾相关文献介绍了该病例的要点。

相似文献

1
Ocular surface disease: a case of vernal keratoconjunctivitis.眼表疾病:春季角结膜炎病例。
Cont Lens Anterior Eye. 2011 Feb;34(1):39-44. doi: 10.1016/j.clae.2010.09.002. Epub 2010 Oct 25.
2
Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes.春季角结膜炎:一种伴有重塑改变的严重过敏性眼部疾病。
Pediatr Allergy Immunol. 2014 Jun;25(4):314-22. doi: 10.1111/pai.12197. Epub 2014 Jan 20.
3
Tailored approach to the treatment of vernal keratoconjunctivitis.个体化治疗春季角结膜炎。
Ophthalmology. 2010 Jul;117(7):1294-9. doi: 10.1016/j.ophtha.2009.11.043. Epub 2010 Apr 10.
4
Vernal keratoconjunctivitis in Thailand.泰国的春季角结膜炎
Asian Pac J Allergy Immunol. 2003 Mar;21(1):25-30.
5
Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis.角膜和结膜结构细胞在春季角结膜炎发病机制中的作用
Prog Retin Eye Res. 2006 Mar;25(2):165-87. doi: 10.1016/j.preteyeres.2005.09.002. Epub 2006 Jan 19.
6
Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis.93例春季角结膜炎患儿病例系列中的长睫毛情况
Pediatrics. 2005 Jan;115(1):e86-91. doi: 10.1542/peds.2004-1555.
7
A clinicopathological analysis of the efficacy of lodoxamide 0.1% eye drops on the conjunctiva of patients with vernal keratoconjunctivitis seen at Guinness Eye Centre, Lagos University Teaching Hospital.对拉各斯大学教学医院吉尼斯眼科中心就诊的春季角结膜炎患者使用0.1%洛度沙胺滴眼液治疗结膜疗效的临床病理分析
Niger Postgrad Med J. 2006 Mar;13(1):35-40.
8
Emerging drugs for ocular allergy.眼部过敏的新型药物
Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. doi: 10.1517/14728214.10.3.505.
9
The differences of tear function and ocular surface findings in patients with atopic keratoconjunctivitis and vernal keratoconjunctivitis.特应性角结膜炎和春季角结膜炎患者泪液功能及眼表表现的差异
Allergy. 2007 Aug;62(8):917-25. doi: 10.1111/j.1398-9995.2007.01414.x.
10
Clinical grading of vernal keratoconjunctivitis.春季角结膜炎的临床分级
Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):436-41. doi: 10.1097/ACI.0b013e3282efb726.

引用本文的文献

1
Vernal Keratoconjunctivitis: Immunopathological Insights and Therapeutic Applications of Immunomodulators.春季角结膜炎:免疫病理学见解及免疫调节剂的治疗应用
Life (Basel). 2024 Mar 9;14(3):361. doi: 10.3390/life14030361.
2
Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles.过敏性结膜炎中的细胞因子:揭示其病理生理作用
Life (Basel). 2024 Mar 7;14(3):350. doi: 10.3390/life14030350.
3
Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives.春季角结膜炎的免疫药理学:现状与未来展望
Pharmaceuticals (Basel). 2021 Jul 9;14(7):658. doi: 10.3390/ph14070658.
4
Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis.0.25%阿伐斯汀滴眼液治疗过敏性结膜炎的研究进展及临床应用
Clin Ophthalmol. 2015 Jul 8;9:1215-25. doi: 10.2147/OPTH.S63790. eCollection 2015.
5
Corneal biochemical features of patients with vernal keratoconjunctivitis.春季角结膜炎患者的角膜生化特征。
Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):555-8. doi: 10.1007/s00417-012-2089-2. Epub 2012 Jun 22.